Leap Therapeutics Inc (LPTX) - Market Cap to Net Income Ratio

Corporate emblem and logo of Leap Therapeutics Inc (LPTX)

Leap Therapeutics, Inc. (LPTX) develops targeted oncology treatments, leveraging exclusive antibody rights to maintain pricing power. The business remains resilient to market volatility, as development is tied to clinical trial milestones. However, logistical risks and patent disputes in Asia create complexities. This price chart featuring the -1.30 indicator confirms these fundamental aspects of the company's operations.

LPTX leaptx.com: Price to Earnings Ratio in the range 07/04/2022 - 11/13/2025

Analytical breakdowns for Leap Therapeutics, Inc.

Comprehensive company analysis:LPTX Leap Tx
Manufactured product of Leap Therapeutics, Inc.

Investors must strip away speculative expectations by utilizing the P/E ratio chart to assess the relationship between Leap Therapeutics, Inc. (LPTX) market capitalization and actual net income. Since Leap Therapeutics, Inc. (LPTX) relies on licensing royalties from the development of oncology drugs, this indicator allows for a comparison of the business value against its fundamental ability to generate income, determining a fair asset valuation independent of temporary market hype.

Competing companies

Market Cap to Earnings ImmunityBio IBRX|P/E Multiple IMCR|Janux Therapeutics (JANX) - Market Cap to Net Income Ratio|Arcus Biosciences Inc - Price to Earnings Ratio|Zymeworks (ZYME) - Market Cap to Earnings|TNGX: Price to Earnings Ratio|Company Value to Net Income IOVA (Iovance Biotherapeutics, Inc.)|IMTX: P/E Multiple|XNCR - Business Payback Period|Price to Earnings Ratio compasstherapeutics.com|Price to Earnings Ratio replimune.com (REPL)|Price to Earnings Ratio Lyell (LYEL)|Price to Earnings Ratio Innate Pharma, S.A. IPHA|Pyxis Oncology Inc. - Price to Earnings Ratio|P/E Multiple Compugen Ltd. CGEN|IOBT - Price to Earnings Ratio|STRO (sutrobio.com) - Price to Earnings Multiple|MiNK Therapeutics, Inc (INKT) - Price to Earnings Ratio|Market Cap to Earnings Werewolf Therapeutics (HOWL)|Price to Earnings Ratio IMMX|ALXO - Market Cap to Net Income Ratio|P/E Multiple CUE|Market Price to Net Income Ratio PDSB|P/E Multiple SONN (Sonnet BioTherapeutics)|Company Value to Net Income MAIA|liminatuspharma.com - P/E Multiple|Market Cap to Earnings LAVA Therapeutics|NextCure, Inc. (NXTC) - Price to Earnings Ratio|Intensity Therapeutics Inc - Company Value to Net Income|SNSE (Sensei Bio) - P/E Multiple|P/E Multiple Theriva Biologics Inc|Price to Earnings Ratio gritstonebio.com (GRTS)|P/E Multiple Kineta Bio (KA)|NexImmune Inc - Price to Earnings Ratio|turnstonebio.com (TSBX) - Market Cap to Earnings|VCNX: Price to Earnings Ratio|Company Value to Net Income HARP (Harpoon Therapeutics, Inc.)